Clinicians and police are positioned to help persons experiencing homelessness, but little has been said about how their best impulses to serve could most productively overlap.
AMA J Ethics. 2021;23(11):E881-886. doi:
10.1001/amajethics.2021.881.
The high prevalence of violence experienced by Native American women and femme-identifying individuals requires clinicians and staff to better understand social determinants of violence.
AMA J Ethics. 2020;22(10):E888-892. doi:
10.1001/amajethics.2020.888.
Pharma has long marketed opioids in ways that contribute to opioid use disorder and deaths by overdose. Regulatory mistakes in approving and labeling new analgesics by the FDA didn’t make us safer.
AMA J Ethics. 2020;22(8):E743-750. doi:
10.1001/amajethics.2020.743.
Upcoding and misrepresenting clinical information constitute fraud, cost a lot, and can result in patient harm and unnecessary procedures and prescriptions.
AMA J Ethics. 2020;22(3):E221-231. doi:
10.1001/amajethics.2020.221.
Professor john powell joins us for this special edition of Ethics Talk to discuss how a lens of “othering and belonging” can help us navigate our obligations to and relationships with each other, especially during this COVID-19 pandemic.
Conflicts of interest must be acknowledged with sincerity and earnestness and managed such that the conflict is eliminated or, at least, credibly mitigated.
AMA J Ethics. 2023;25(3):E186-193. doi:
10.1001/amajethics.2023.186.
Rebekah Davis Reed, PhD, JD and Erik L. Antonsen, PhD, MD
Though the National Aeronautics and Space Administration’s collection of disaggregated genetic data for occupational surveillance and research raises numerous privacy concerns, the Genetic Information Nondiscrimination Act of 2008 allows genetic information to be used to develop personal pharmaceuticals.
AMA J Ethics. 2018;20(9):E849-856. doi:
10.1001/amajethics.2018.849.
Physicians should not only avoid forming personal relationships with drug reps but must also acquire and apply numeracy skills and information management strategies to critically evaluating drug reps’ information.
AMA J Ethics. 2015;17(8):729-733. doi:
10.1001/journalofethics.2015.17.8.ecas1-1508.